PDCD1 and neoplasm: As expected, targeting of METTL3 plus anti-PD-1 exerted the strongest inhibitory effect on tumor growth in vivo (Figures 7G and 7H), concomitant with the highest level of intratumor IFN-γ+ and GZMB+ CD8+ T cells (Figure 7I).